NASDAQ:CTSO Cytosorbents (CTSO) Stock Price, News & Analysis $1.04 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.02 -0.02 (-1.44%) As of 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Cytosorbents Stock (NASDAQ:CTSO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cytosorbents alerts:Sign Up Key Stats Today's Range$1.00▼$1.0750-Day Range$0.81▼$1.0852-Week Range$0.70▼$1.59Volume56,307 shsAverage Volume601,488 shsMarket Capitalization$56.87 millionP/E RatioN/ADividend YieldN/APrice Target$4.67Consensus RatingBuy Company OverviewCytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Read More… Cytosorbents Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreCTSO MarketRank™: Cytosorbents scored higher than 52% of companies evaluated by MarketBeat, and ranked 621st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCytosorbents has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCytosorbents has only been the subject of 2 research reports in the past 90 days.Read more about Cytosorbents' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytosorbents are expected to grow in the coming year, from ($0.30) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytosorbents is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytosorbents is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytosorbents has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cytosorbents' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.65% of the outstanding shares of Cytosorbents have been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Cytosorbents has recently increased by 3.57%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytosorbents does not currently pay a dividend.Dividend GrowthCytosorbents does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.65% of the outstanding shares of Cytosorbents have been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Cytosorbents has recently increased by 3.57%, indicating that investor sentiment is decreasing. News and Social Media2.7 / 5News Sentiment0.83 News SentimentCytosorbents has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cytosorbents this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for CTSO on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Cytosorbents insiders have bought more of their company's stock than they have sold. Specifically, they have bought $29,313.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.60% of the stock of Cytosorbents is held by insiders.Percentage Held by InstitutionsOnly 32.87% of the stock of Cytosorbents is held by institutions.Read more about Cytosorbents' insider trading history. Receive CTSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter. Email Address CTSO Stock News HeadlinesStockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)January 21, 2025 | americanbankingnews.comCytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights OfferingJanuary 13, 2025 | markets.businessinsider.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.January 27, 2025 | Crypto Swap Profits (Ad)Expert Outlook: CytoSorbents Through The Eyes Of 7 AnalystsJanuary 13, 2025 | benzinga.comCytoSorbents closes oversubscribed rights offeringJanuary 13, 2025 | msn.comCytoSorbents opens regional sales subsidiary in DubaiJanuary 6, 2025 | markets.businessinsider.comCytoSorbents sees Q4 product revenue $9M-$9.2M vs. $7.35M last yearJanuary 5, 2025 | markets.businessinsider.comCytoSorbents reported strong Q4 results, says D. Boral CapitalJanuary 4, 2025 | finance.yahoo.comSee More Headlines CTSO Stock Analysis - Frequently Asked Questions How have CTSO shares performed this year? Cytosorbents' stock was trading at $0.91 at the beginning of 2025. Since then, CTSO stock has increased by 14.3% and is now trading at $1.04. View the best growth stocks for 2025 here. How were Cytosorbents' earnings last quarter? Cytosorbents Co. (NASDAQ:CTSO) released its quarterly earnings data on Thursday, November, 7th. The medical research company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.03. The medical research company had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.14 million. Cytosorbents had a negative net margin of 49.47% and a negative trailing twelve-month return on equity of 118.54%. Who are Cytosorbents' major shareholders? Cytosorbents' top institutional investors include Sargent Investment Group LLC (2.28%). Insiders that own company stock include Phillip P Chan, Vincent Capponi, Peter J Mariani, Al Kraus, Alan D Sobel, Michael G Bator, Edward Raymond Jones, Jiny Kim and Kathleen P Bloch. View institutional ownership trends. How do I buy shares of Cytosorbents? Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytosorbents investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Corning (GLW), UnitedHealth Group (UNH) and DocuSign (DOCU). Company Calendar Last Earnings11/07/2024Today1/27/2025Next Earnings (Estimated)3/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:CTSO CUSIPN/A CIK1175151 Webwww.cytosorbents.com Phone(732) 329-8885Fax732-329-8650Employees220Year FoundedN/APrice Target and Rating Average Stock Price Target$4.67 High Stock Price Target$10.00 Low Stock Price Target$1.00 Potential Upside/Downside+348.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,510,000.00 Net Margins-49.47% Pretax Margin-51.62% Return on Equity-118.54% Return on Assets-42.31% Debt Debt-to-Equity Ratio1.06 Current Ratio1.97 Quick Ratio1.58 Sales & Book Value Annual Sales$36.35 million Price / Sales1.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book2.00Miscellaneous Outstanding Shares54,680,000Free Float51,071,000Market Cap$56.87 million OptionableOptionable Beta0.58 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:CTSO) was last updated on 1/27/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytosorbents Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytosorbents With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.